1. Finkel S, Costa e Silva J, Cohen G, et al. Behavioral and psychological symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Am J Geriatr Psychiatry 1998;6:97-100.
2. The Expert Consensus Panel for Agitation in Dementia. Treatment of agitation in older persons with dementia. Postgrad Med 1998;4(suppl):1-88.
3. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry 2001;9(4):361-81.
4. Davidson J. Pharmacologic treatment. In: Busse E, Blazer D (eds). Textbook of geriatric psychiatry (2nd ed). Washington DC: American Psychiatric Publishing, 1996:359-79.
5. Nies A, Robinson DS, Friedman MJ, et al. Relationship between age and tricyclic antidepressant plasma levels. Am J Psychiatry 1977;134(7):790-3.
6. Greenblatt DJ, Shader RJ. Benzodiazepine kinetics in the elderly. In: Usdin E (ed). Clinical pharmacology in psychiatry. New York: Elsevier, 1981;174-81.
7. Pollock BG, Perel JM, Altieri LP, et al. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology. Psychopharmacol Bull. 1992;28(2):163-8.
8. Nelson JC, Atillasoy E, Mazure C, Jatlow PI. Hydroxydesipramine in the elderly. J Clin Psychopharmacol 1988;8(6):428-33.
9. Young RC, Alexopoulos GS, Shamoian CA, et al. Plasma 10-hydroxynortriptyline in elderly depressed patients. Clin Pharmacol Ther 1984;35(4):540-4.
10. Cantillon M, Molchan SE, Little J. Pharmacological and neuroendocrine probes in neuropsychiatric illness. In: Coffey CE, Cummings JL (eds). Textbook of geriatric neuropsychiatry. Washington, DC: American Psychiatric Publishing, 1994.
11. Young RC, Meyers BS. Psychopharmacology. In: Sadovoy J, Lazarus LW, Jarvik LF, Grossberg GT (eds). Comprehensive review of geriatric psychiatry. Washington DC: American Psychiatric Publishing, 1996;755-817.
12. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999;60(2):107-15.
13. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000;57(10):968-76.
14. Tariot PN, Salzman C, Yeung PP, et al. Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther 2000;22(9):1068-84.
15. Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997;58(suppl):55-62.
16. Pickar D. Prospects for pharmacotherapy of schizophrenia. Lancet 1995;345:557-62.
17. Kasckow JW, McElroy SL, Cameron RL, et al. A pilot study on the use of divalproex sodium in the treatment of behavioral agitation in elderly patients with dementia: assessment with the BEHAVE-AD and CGI rating scales. Curr Ther Res 1997;58(12):981-9.
18. Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998;155(1):54-61.
19. Kasckow JW. Cognitive enhancers for dementia: do they work? Current Psychiatry 2002;1(3):22-8.
20. Lacy C, Armstrong L, Goldman M, Lance L. (eds) Lexicomp drug information handbook. Hudson, OH: Lexicomp, 2003-2004:1225-27, 1189-90, 1026-27.
21. Jeste DV, Lacro JP, Bailey A, et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999;47(6):716-19.
22. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45(9):789-96.
23. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995;52(9):756-65.
24. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-6.
25. Chengappa KN, Baker RW, Kreinbrook SB, Adair D. Clozapine use in female geriatric patients with psychoses. JGeriatr Psychiatry Neurol 1995;8(1):12-15.
26. Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in the nursing home. J Gerontol 1989;44(3):M77-84.
27. Lavretsky H, Sultzer D. A structured trial of risperidone for the treatment of agitation in dementia. Am J Geriatr Psychiatry 1998;6(2):127-35.
28. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999;53(5):946-55.
29. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003;64(2):134-43.
30. Satterlee W, Reams SG, Burns PR, et al. A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer’s disease patients (abstract). Psychopharmacol Bull 1995;31:534.-
31. Berkowitz A. Ziprasidone for elderly dementia: a case series (abstract). San Francisco, CA: American Psychiatric Association annual meeting, 2003.
32. De Deyn PP, Jeste D, Auby P, Carson W. Aripiprazole in dementia of the Alzheimer’s type (abstract). Honolulu, HI: American Association for Geriatric Psychiatry annual meeting, 2003.